Human immunoglobulin G
- Generic Name
- Human immunoglobulin G
- Brand Names
- Asceniv, Bivigam, Cuvitru, Flebogamma, Gamastan, Gammagard, Gammaked, Gammaplex, Gamunex, Hizentra, Hyqvia 5 G / 50 Ml Kit, Igivnex, Kiovig, Octagam, Panzyga, Privigen, Xembify, HyQvia, Flebogamma DIF (previously Flebogammadif)
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 308067-58-5
- Unique Ingredient Identifier
- 66Y330CJHS
- Background
Intravenous immunoglobulin (IVIg) is a mixture of IgG1 and other antibodies derived from healthy human plasma via Cohn fractionation. The purification process includes cold alcohol fractionation, polyethylene glycol precipitation, and ion exchange chromatography. IVIg contains the same distribution of IgG antibody subclasses as is found in the general human ...
- Indication
Human immunoglobulin G is indicated for the following conditions:
- Associated Conditions
- Acute Idiopathic Thrombocytopenic Purpura, Bacterial Infections, Chronic Idiopathic Thrombocytopenic Purpura, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, Coronary Artery Aneurysm, Dermatomyositis (DM), Hepatitis A, Measles, Multifocal Motor Neuropathy (MMN), Primary humoral immunodeficiency, Rubella, Secondary humoral immunodeficiency, Varicella
- Associated Therapies
- Maintenance therapy
Stem Cell Transplant for Immunologic or Histiocytic Disorders
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2005-09-15
- Last Posted Date
- 2017-12-28
- Lead Sponsor
- Masonic Cancer Center, University of Minnesota
- Target Recruit Count
- 19
- Registration Number
- NCT00176865
- Locations
- 🇺🇸
Masonic Cancer Center University of Minnesota, Minneapolis, Minnesota, United States
Intravenous Immunoglobulin (IVIg) for the Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Phase 2
Completed
- Conditions
- First Posted Date
- 2002-12-10
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 60
- Registration Number
- NCT00001287
- Locations
- 🇺🇸
National Institute of Neurological Disorders and Stroke (NINDS), Bethesda, Maryland, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2024. All Rights Reserved by MedPath